Immunotherapy for prostate cancer: Requirements for a successful regime transfer

Despite the revolutionary progress in cancer treatment using immune checkpoint inhibitors (ICIs), remarkable responses in prostate cancer treatment have not yet been achieved. The disappointing previous results of ICIs have required further studies towards combined treatment targeting other pathways...

Full description

Saved in:
Bibliographic Details
Published inInvestigative and clinical urology Vol. 63; no. 1; pp. 3 - 13
Main Authors Jeong, Seung-Hwan, Kwak, Cheol
Format Journal Article
LanguageEnglish
Published Korea (South) The Korean Urological Association 01.01.2022
Korean Urological Association
Subjects
Humans
Immunotherapy
Male
prostatic neoplasms
Prostatic Neoplasms - pathology
Prostatic Neoplasms - therapy
Review
Tumor Microenvironment
Tumor microenvironment
Immunotherapy
Prostatic neoplasms
Online AccessGet full text

Cover

More Information
Summary:Despite the revolutionary progress in cancer treatment using immune checkpoint inhibitors (ICIs), remarkable responses in prostate cancer treatment have not yet been achieved. The disappointing previous results of ICIs have required further studies towards combined treatment targeting other pathways and restricted the eligibility criteria for patients with high mutation burdens, especially those with mismatch repair deficiency. Cancer immunotherapies activate adaptive immune systems, rather than directly attack tumor cells with their own cytotoxicity. Therefore, refractoriness to ICIs can not only be derived from the intractable nature of tumor cells , but also from their hostile milieu. Here, we reviewed the prostate cancer immunotherapies exploring clinical trials to date, along with the molecular characteristics of prostate cancer and its microenvironment.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:2466-0493
2466-054X
DOI:10.4111/ICU.20210369